Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Entrada Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

-- COMPANY TO REPORT ELEVATE-44-201 DATA FROM COHORT 1 OPEN-LABEL PERIOD BY YEAR-END 2026 -- -- ELEVATE-44-201 COHORT 2 ENROLLMENT COMPLETE WITH DATA EXPECTED IN Q1 2027 -- -- COMPANY TO REPORT ELEVATE-45-201 COHORT 1 DATA IN OCTOBER 2026 -- -- ELEVATE-45-201 COHORT 2 DOSING ONGOING AT THE INCREASED DOSE OF 10 MG/KG WITH DATA EXPECTED IN H1 2027 -- -- VERTEX TO REPORT VX-670 PHASE 1/2 DATA IN PEOPLE LIVING WITH DM1 IN H2 2026 -- BOSTON, AUG. 05, 2026 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND HIGHLIGHTED RECENT BUSINESS UPDATES. WITH MULTIPLE DATA READOUTS AHEAD IN 2026, WE ARE WELL POSITIONED TO DELIVER ON IMPORTANT CLINICAL MILESTONES AND FURTHER DEMONSTRATE THE POTENTIAL OF OUR DMD FRANCHISE, SAID DIPAL DOSHI, CHIEF EXECUTIVE OFFICER OF ENTRADA THERAPEUTICS.

ENTRADA THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

NEW YORK, JUNE 4, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ENTRADA THERAPEUTICS, INC. ("ENTRADA" OR THE "COMPANY") (NASDAQ: TRDA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ENTRADA THERAPEUTICS, INC. - TRDA

NEW YORK, JUNE 02, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ENTRADA THERAPEUTICS, INC. (ENTRADA OR THE COMPANY) (NASDAQ: TRDA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

-- PARTICIPANTS IN COHORT 1 HAVE PROGRESSED TO THE OPEN-LABEL, PHASE 2 PORTION OF ELEVATE-45-201 -- -- COMPANY ON TRACK TO REPORT ELEVATE-45-201 COHORT 1 DATA IN MID-2026 -- BOSTON, JUNE 02, 2026 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED THAT AN INDEPENDENT DATA MONITORING COMMITTEE (DMC), PER STUDY PROTOCOL, HAS REVIEWED ALL AVAILABLE SAFETY AND PK DATA FROM THE EIGHT PARTICIPANTS ENROLLED IN COHORT 1 OF THE DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE (MAD) PORTION OF ELEVATE-45-201. THE DMC RECOMMENDED INITIATION OF THE COHORT 2 DOSE AT 10 MG/KG, A DOSE ESCALATION FROM 5 MG/KG IN COHORT 1.

INDEPENDENT SAFETY DATA MONITORING COMMITTEE RECOMMENDS INITIATION OF COHORT 2 AT THE INCREASED DOSE OF 10 MG/KG IN ENTRADA THERAPEUTICS' ELEVATE-45-201 STUDY

BOSTON, JUNE 01, 2026 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED THAT THE COMPANY GRANTED AN AGGREGATE OF 18,600 RESTRICTED STOCK UNITS (RSUS) TO THREE NEWLY-HIRED NON-EXECUTIVE EMPLOYEES UNDER THE COMPANY'S 2025 INDUCEMENT EQUITY PLAN (THE INDUCEMENT PLAN), EFFECTIVE AS OF JUNE 1, 2026. THE INDUCEMENT GRANTS WERE PREVIOUSLY APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS, AS A MATERIAL INDUCEMENT TO THE NEW EMPLOYEES' ENTRY INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ENTRADA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NEW YORK, MAY 28, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ENTRADA THERAPEUTICS, INC. ("ENTRADA" OR THE "COMPANY") (NASDAQ: TRDA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, MAY 26, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ENTRADA THERAPEUTICS, INC. (ENTRADA OR THE COMPANY) (NASDAQ: TRDA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

NEW YORK, MAY 21, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ENTRADA THERAPEUTICS, INC. ("ENTRADA" OR THE "COMPANY") (NASDAQ: TRDA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK, MAY 19, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ENTRADA THERAPEUTICS, INC. (ENTRADA OR THE COMPANY) (NASDAQ: TRDA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

NEW YORK, MAY 14, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ENTRADA THERAPEUTICS, INC. ("ENTRADA" OR THE "COMPANY") (NASDAQ: TRDA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

Entrada Therapeutics, Inc.

TRDA

Price

Financial Reports

No items found.

Press Releases

Entrada Therapeutics, Inc.

TRDA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TRDA